CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: D2HGDH (ImmuneEditome ID:728294)

1. Gene summary of enriched editing regions for D2HGDH

check button Gene summary
Gene informationGene symbol

D2HGDH

Gene ID

728294

GeneSynonymsD2HGD
GeneCytomap

2q37.3

GeneTypeprotein-coding
GeneDescriptionD-2-hydroxyglutarate dehydrogenase, mitochondrial
GeneModificationdate20230329
UniprotIDG5E9E8;Q8N465;H7C290;H7C3L2;F8WCF9;B5MCV2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:241746450-241748350:+ENST00000321264.7ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241746450-241748350:+ENST00000400769.5ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241746450-241748350:+ENST00000403782.4ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241746450-241748350:+ENST00000417686.1ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241746450-241748350:+ENST00000436747.4ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241746450-241748350:+ENST00000437164.1ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241746450-241748350:+ENST00000454048.1ENSG00000180902.15D2HGDHintronicAluSx1,AluSz,AluSg,L1MEd,AluJochr2:241746450-241748350:+.alignment
chr2:241757733-241758923:+ENST00000468064.4ENSG00000180902.15D2HGDHncRNA_intronicL1MEd,AluJo,AluJb,AluJr,AluSq2,(TG)nchr2:241757733-241758923:+.alignment
chr2:241757733-241758923:+ENST00000470343.4ENSG00000180902.15D2HGDHncRNA_intronicL1MEd,AluJo,AluJb,AluJr,AluSq2,(TG)nchr2:241757733-241758923:+.alignment
chr2:241757733-241758923:+ENST00000473126.1ENSG00000180902.15D2HGDHncRNA_intronicL1MEd,AluJo,AluJb,AluJr,AluSq2,(TG)nchr2:241757733-241758923:+.alignment
chr2:241757733-241758923:+ENST00000486953.4ENSG00000180902.15D2HGDHncRNA_intronicL1MEd,AluJo,AluJb,AluJr,AluSq2,(TG)nchr2:241757733-241758923:+.alignment
chr2:241761256-241762350:+ENST00000468064.4ENSG00000180902.15D2HGDHncRNA_intronicAluSq,AluSg,MER2chr2:241761256-241762350:+.alignment
chr2:241761256-241762350:+ENST00000470343.4ENSG00000180902.15D2HGDHncRNA_intronicAluSq,AluSg,MER2chr2:241761256-241762350:+.alignment
chr2:241761256-241762350:+ENST00000473126.1ENSG00000180902.15D2HGDHncRNA_intronicAluSq,AluSg,MER2chr2:241761256-241762350:+.alignment
chr2:241761256-241762350:+ENST00000486953.4ENSG00000180902.15D2HGDHncRNA_intronicAluSq,AluSg,MER2chr2:241761256-241762350:+.alignment


Top

2. Tumor-specific enriched editing regions for D2HGDH


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:241746450-241748350:+BRCAEER8.8819e-03image
ENSG00000180902.15,D2HGDHBRCAEAG4.7275e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr2:241757733-241758923:+ESCAEER2.6950e-022.1299e-021.4390e-03image
chr2:241746450-241748350:+LAMLEER1.2079e-023.3925e-034.3899e+02image

Top

3. Enriched editing regions and immune related genes for D2HGDH


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for D2HGDH


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for D2HGDH


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:241746450-241748350:+BLCAEERMonocytes3.9292e-02-0.3451image
ENSG00000180902.15,D2HGDHBLCAEAGMonocytes3.0482e-02-0.2666image
chr2:241746450-241748350:+BRCAEERNK_cells_activated2.2265e-030.1801image
ENSG00000180902.15,D2HGDHBRCAEAGNK_cells_activated1.0968e-020.1319image
ENSG00000180902.15,D2HGDHCESCEAGMacrophages_M22.9006e-030.4434image
ENSG00000180902.15,D2HGDHCOADEAGT_cells_regulatory_(Tregs)4.1715e-02-0.2707image
chr2:241757733-241758923:+ESCAEERT_cells_CD84.8447e-02-0.4158image
ENSG00000180902.15,D2HGDHGBMEAGMonocytes2.0466e-020.4800image
chr2:241746450-241748350:+KIRCEERT_cells_CD4_memory_resting9.4471e-030.3298image
ENSG00000180902.15,D2HGDHKIRCEAGDendritic_cells_resting1.0889e-030.3284image
ENSG00000180902.15,D2HGDHKIRPEAGT_cells_CD4_memory_activated8.9015e-080.6776image
chr2:241746450-241748350:+LAMLEERT_cells_regulatory_(Tregs)1.2879e-060.4872image
ENSG00000180902.15,D2HGDHLAMLEAGT_cells_regulatory_(Tregs)5.2595e-050.3740image
ENSG00000180902.15,D2HGDHLGGEAGT_cells_CD81.7019e-02-0.1946image
chr2:241746450-241748350:+LUADEERT_cells_CD4_memory_activated5.7242e-040.2885image
ENSG00000180902.15,D2HGDHLUADEAGT_cells_CD4_memory_activated6.8114e-050.2940image
chr2:241746450-241748350:+LUSCEEREosinophils2.8265e-02-0.2152image
chr2:241746450-241748350:+OVEERT_cells_CD4_memory_resting1.5692e-020.2694image
ENSG00000180902.15,D2HGDHOVEAGT_cells_CD87.6360e-030.2455image
chr2:241746450-241748350:+PAADEERMonocytes4.5512e-02-0.3678image
chr2:241746450-241748350:+PCPGEERMonocytes4.3017e-02-0.3491image
ENSG00000180902.15,D2HGDHPCPGEAGMonocytes2.6523e-02-0.3464image
ENSG00000180902.15,D2HGDHPRADEAGMonocytes1.4660e-02-0.2365image
chr2:241746450-241748350:+SKCMEERT_cells_gamma_delta1.8035e-060.6951image
ENSG00000180902.15,D2HGDHSKCMEAGT_cells_gamma_delta1.7794e-060.6226image
chr2:241746450-241748350:+STADEERMonocytes2.0553e-020.2412image
chr2:241757733-241758923:+STADEERMast_cells_activated4.2030e-020.4585image
ENSG00000180902.15,D2HGDHSTADEAGMonocytes3.8932e-020.1972image
ENSG00000180902.15,D2HGDHTHCAEAGMast_cells_activated2.2123e-020.2879image


Top

6. Enriched editing regions and immune gene sets for D2HGDH


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000180902.15,D2HGDHBLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.8461e-020.2554image
ENSG00000180902.15,D2HGDHBRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.5185e-030.1564image
chr2:241746450-241748350:+BRCAGSVA_HALLMARK_P53_PATHWAYEER1.6336e-050.2518image
chr2:241757733-241758923:+BRCAGSVA_HALLMARK_GLYCOLYSISEER1.9494e-02-0.2984image
chr2:241746450-241748350:+CESCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.8008e-02-0.4308image
ENSG00000180902.15,D2HGDHCESCGSVA_HALLMARK_NOTCH_SIGNALINGEAG6.0761e-03-0.4118image
chr2:241746450-241748350:+ESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.9801e-020.2599image
ENSG00000180902.15,D2HGDHGBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.0417e-020.5232image
chr2:241746450-241748350:+KIRCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.7598e-040.4409image
chr2:241757733-241758923:+KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.7007e-020.4822image
ENSG00000180902.15,D2HGDHKIRCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.9915e-050.4123image
ENSG00000180902.15,D2HGDHKIRPGSVA_HALLMARK_APICAL_SURFACEEAG1.1243e-02-0.3592image
ENSG00000180902.15,D2HGDHLAMLGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.3871e-030.2855image
chr2:241746450-241748350:+LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEER9.0647e-03-0.2752image
chr2:241746450-241748350:+LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.3250e-030.2474image
ENSG00000180902.15,D2HGDHLUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.6764e-030.2111image
ENSG00000180902.15,D2HGDHOVGSVA_HALLMARK_HEME_METABOLISMEAG5.3870e-03-0.2557image
chr2:241746450-241748350:+PCPGGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.5532e-02-0.4118image
ENSG00000180902.15,D2HGDHPRADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.6471e-04-0.3161image
ENSG00000180902.15,D2HGDHSARCGSVA_HALLMARK_NOTCH_SIGNALINGEAG6.9081e-030.5584image
ENSG00000180902.15,D2HGDHSKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1956e-020.3564image
chr2:241746450-241748350:+SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.0785e-030.4900image
ENSG00000180902.15,D2HGDHSTADGSVA_HALLMARK_APICAL_SURFACEEAG3.3417e-030.2774image
chr2:241746450-241748350:+STADGSVA_HALLMARK_APICAL_SURFACEEER8.3426e-030.2735image
chr2:241746450-241748350:+THYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.7723e-030.6064image
ENSG00000180902.15,D2HGDHTHYMGSVA_HALLMARK_GLYCOLYSISEAG2.8589e-020.3421image


Top

7. Enriched editing regions and drugs for D2HGDH


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000180902.15,D2HGDHBLCABMS.708163EAG2.7208e-02-0.2719image
chr2:241746450-241748350:+BLCACGP.082996EER1.8005e-02-0.3922image
ENSG00000180902.15,D2HGDHBRCAGNF.2EAG1.6904e-04-0.1941image
chr2:241746450-241748350:+BRCAGNF.2EER2.1979e-07-0.3006image
chr2:241757733-241758923:+BRCABI.D1870EER1.3816e-020.3137image
chr2:241746450-241748350:+CESCCamptothecinEER1.4600e-02-0.4733image
ENSG00000180902.15,D2HGDHCESCIPA.3EAG8.3828e-03-0.3970image
chr2:241757733-241758923:+ESCAJNK.9LEER1.6702e-020.4935image
ENSG00000180902.15,D2HGDHESCAAKT.inhibitor.VIIIEAG9.2688e-030.2840image
chr2:241746450-241748350:+ESCAAMG.706EER2.2531e-03-0.3593image
ENSG00000180902.15,D2HGDHGBMAICAREAG3.6930e-03-0.5804image
chr2:241746450-241748350:+KIRCJNK.Inhibitor.VIIIEER2.6526e-030.3782image
chr2:241757733-241758923:+KIRCMG.132EER2.0051e-02-0.4714image
ENSG00000180902.15,D2HGDHKIRCJNK.Inhibitor.VIIIEAG2.2640e-030.3080image
ENSG00000180902.15,D2HGDHKIRPATRAEAG1.3287e-03-0.4457image
chr2:241746450-241748350:+LAMLA.770041EER8.0445e-05-0.4056image
ENSG00000180902.15,D2HGDHLAMLBicalutamideEAG2.2545e-03-0.2870image
ENSG00000180902.15,D2HGDHLGGGDC0941EAG9.1102e-030.2123image
chr2:241746450-241748350:+LUADCHIR.99021EER1.2198e-020.2128image
ENSG00000180902.15,D2HGDHLUADBMS.708163EAG2.7269e-02-0.1655image
ENSG00000180902.15,D2HGDHLUSCBMS.509744EAG1.5685e-020.2100image
chr2:241746450-241748350:+LUSCEmbelinEER3.2556e-020.2098image
chr2:241746450-241748350:+OVLapatinibEER6.3619e-03-0.3026image
ENSG00000180902.15,D2HGDHOVEmbelinEAG2.9480e-030.2726image
chr2:241746450-241748350:+PCPGAZD6244EER1.2693e-040.6103image
ENSG00000180902.15,D2HGDHPCPGAZD6244EAG4.3841e-030.4359image
ENSG00000180902.15,D2HGDHPRADJNK.9LEAG5.9204e-030.2656image
ENSG00000180902.15,D2HGDHSARCCytarabineEAG3.1661e-03-0.5999image
chr2:241746450-241748350:+SKCMMethotrexateEER4.3321e-02-0.3436image
ENSG00000180902.15,D2HGDHSKCMCEP.701EAG6.8953e-03-0.3811image
chr2:241746450-241748350:+STADFTI.277EER2.1634e-020.2392image
chr2:241757733-241758923:+STADMG.132EER1.6149e-020.5304image
ENSG00000180902.15,D2HGDHTHCAGNF.2EAG2.1424e-02-0.2894image
chr2:241746450-241748350:+THYMElesclomolEER2.3057e-02-0.4822image
ENSG00000180902.15,D2HGDHTHYMAG.014699EAG2.3225e-020.3539image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType